Document is current
Any future updates will be listed below
-
Authors
Yue, Pinli
Bie, Fenglong
Zhu, Jiarun
Gao, Lin-Rui
Zhou, Zhendiao
Bai, Guangyu
Wang, Xiaobing
Zhao, Ziyi
Xiao, Ze-Fen
Li, Yong
Zhou, Aiping
Liu, Wen-Yang
Jiao, Yuchen
Gao, Shugeng
-
Funding
Funding for this research was provided by:
National Key R&D Program of China (2021YFC2500900)
National Natural Science Foundation Fund (82225033)
Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences (2021-I2M-1-015, 2021-1-I2M-018, and 2021-I2M-1-067, 2021-I2M-1-015, 2021-1-I2M-018, and 2021-I2M-1-067)
Non-profit central research institute fund of Chinese Academy of Medical Sciences (2022-RC310-08)
Beijing Marathon of Hope, Cancer Foundation of China (LC2022R01)
- License Information
-
More Information
Article History
Received: 23 January 2024
Accepted: 19 April 2024
First Online: 10 May 2024
Declarations
:
: The study was approved by the Ethics Committee of National Cancer Center, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (approval numbers: 20/112–2308 and and 22/036-3237). All participants provided written informed consent.
: Not applicable.
: Y.J. is one of the cofounders of Genetron Holdings, has owner interest in Genetron Holdings, and receives royalties from Genetron. Other authors declare no conflict of interest.
